EVC2: A novel modulator in tooth development

EVC2:牙齿发育的新型调节剂

基本信息

  • 批准号:
    8074330
  • 负责人:
  • 金额:
    $ 37.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ellis-van Creveld (EVC) syndrome is an autosomal recessive chondrodysplasia with dwarfism. The EVC patients have a short lip bound by frenum to alveolar ridge, which is also described as hyperplastic frena with a shallow labial sulcus, unique to this syndrome. They also have several major dental anomalies including neonatal teeth, partial anodontia, peg-shaped teeth, delayed eruption of permanent teeth and early involvement with caries. Since these dental manifestations are not simply caused by developmental delay, an investigation in this particular syndrome will provide a new insight into the understanding of tooth development. It is now clear that EVC syndrome is caused by mutations in either EVC or EVC2 gene, both of which are located on human chromosome 4p in a head-to-head configuration. A causative gene, LIMBIN for bovine chondrodysplastic dwarfism (bcd) found in Japanese brown cattle was later identified as the bovine ortholog of EVC2, indicating the significance of EVC2 protein function. In order to investigate the pathophysiological mechanism of dwarfism/tooth development seen in EVC patients, Evc2 mutant mice were generated by introducing a premature stop codon in exon12, mimicking mutations found in EVC patients and bcd cattle. As the majority of mutations identified in EVC syndrome are non-sense mutations, they result in premature termination of the peptide causing 'loss of function'. These homozygous mutant mice showed severe dwarfism with dental anomalies similar to EVC patients, indicating a potential animal model of this disease. During our initial characterization, we found several major dental phenotypes in the mutant mice. All teeth were generally hypoplastic in enamel formation. Although incisors were able to grow continuously, they were short in length and upper incisors were poorly erupted (sometimes not erupted) with abnormal direction at the adult stage. At embryonic day 18.5, differentiation of ameloblasts was clearly arrested lacking cell polarization with no apparent microtubules, poor amelogenin secretion and altered matrix metalloproteinase (MMP)-2 expression. The in vitro studies demonstrated that wild type (WT) Evc2 is localized at the Golgi in an ameloblastic cell line, LS8, whereas mutant Evc2 is "mis"localized at the cytoplasm. Moreover, mouse embryonic fibroblasts derived from the Evc2 mutant mouse exhibited poor cell migration and the level of JNK phosphorylation in these cells was markedly reduced when compared to those from WT mouse. These preliminary data led us to hypothesize that EVC2 is critical for the formation of microtubules of ameloblasts that control extracellular matrix (ECM)/MMP protein trafficking and cell migration during tooth development. In order to test this hypothesis, the following specific aims are proposed; Aim1. To characterize the tooth development in Evc2 mutant mice. Aim2. To investigate the effects of human EVC2 mutations on ameloblast cell function. Aim3. To rescue the ameloblast phenotypes by EVC2 mutation. The data obtained from this study will provide new insights into the pathophysiological function of EVC2 in ameloblast cell function and the molecular mechanism for tooth development. PUBLIC HEALTH RELEVANCE: People suffering from Ellis-van Creveld (EVC) syndrome show oral/dental abnormalities including missing/small teeth. In order to investigate the mechanism of dental abnormalities in EVC patients caused by a mutation in EVC2 gene, we have generated Evc2 mutant mice. The goal of our study is to determine when and how these mice develop abnormal teeth, to investigate the effect of Evc2 mutation on the cell movement in teeth, and to rescue the effect of Evc2 mutation.
描述(由申请人提供):Ellis-van Creveld(EVC)综合征是一种常染色体隐性软骨发育不良伴侏儒症。EVC患者的唇短,由系带与牙槽嵴连接,这也被描述为伴有浅唇沟的增生性系带,这是该综合征所特有的。他们也有几个主要的牙齿异常,包括新生儿牙齿,部分缺失,钉状牙齿,恒牙的延迟萌出和早期龋齿。由于这些牙齿表现不仅仅是由发育迟缓引起的,因此对这种特殊综合征的调查将为了解牙齿发育提供新的见解。现在很清楚,EVC综合征是由EVC或EVC 2基因突变引起的,两者都位于人类染色体4p上的头对头构型。在日本褐牛中发现的牛软骨发育不良性侏儒症(bcd)的致病基因LIMBIN后来被鉴定为EVC 2的牛直系同源物,表明EVC 2蛋白功能的重要性。为了研究在EVC患者中观察到的侏儒症/牙齿发育的病理生理学机制,通过在外显子12中引入提前终止密码子来产生Evc 2突变小鼠,模拟在EVC患者和bcd牛中发现的突变。由于在EVC综合征中鉴定的大多数突变是无义突变,它们导致肽的过早终止,从而导致“功能丧失”。这些纯合子突变小鼠表现出严重的侏儒症,牙齿异常类似于EVC患者,表明这种疾病的潜在动物模型。在我们最初的表征,我们发现了几个主要的牙齿表型的突变小鼠。所有牙齿的釉质形成普遍发育不全。虽然门齿能够持续生长,但在成人阶段,门齿长度较短,上门齿萌出不良(有时不萌出),方向异常。在胚胎第18.5天,成釉细胞分化明显受阻,缺乏细胞极化,没有明显的微管,釉原蛋白分泌不良,基质金属蛋白酶(MMP)-2表达改变。体外研究表明,野生型(WT)Evc 2定位于成釉细胞系LS 8的高尔基体,而突变型Evc 2“错“定位于细胞质。此外,来自Evc 2突变小鼠的小鼠胚胎成纤维细胞表现出较差的细胞迁移,并且与来自WT小鼠的那些细胞相比,这些细胞中的JNK磷酸化水平显著降低。这些初步数据使我们假设EVC 2对成釉细胞微管的形成至关重要,成釉细胞微管在牙齿发育过程中控制细胞外基质(ECM)/MMP蛋白的运输和细胞迁移。为了检验这一假设,提出了以下具体目标:目标1。描述Evc 2突变小鼠的牙齿发育特征。目标2。研究人类EVC 2基因突变对成釉细胞功能的影响。目标3。通过EVC 2突变挽救成釉细胞表型。本研究的结果将为EVC 2在成釉细胞功能中的病理生理功能和牙齿发育的分子机制提供新的见解。 公共卫生相关性:患有Ellis-van Creveld(EVC)综合征的人表现出口腔/牙齿异常,包括缺失/小牙齿。为了研究EVC 2基因突变引起的EVC患者牙齿异常的机制,我们产生了EVC 2突变小鼠。本研究的目的是确定这些小鼠何时以及如何发生牙齿异常,研究Evc 2突变对牙齿细胞运动的影响,并挽救Evc 2突变的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YOSHIYUKI MOCHIDA其他文献

YOSHIYUKI MOCHIDA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YOSHIYUKI MOCHIDA', 18)}}的其他基金

EVC2: A novel modulator in tooth development
EVC2:牙齿发育的新型调节剂
  • 批准号:
    8291133
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
EVC2: A novel modulator in tooth development
EVC2:牙齿发育的新型调节剂
  • 批准号:
    7729826
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
Role of Vwc2-assisted activin signaling in bone formation
Vwc2辅助激活素信号在骨形成中的作用
  • 批准号:
    7893658
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
EVC2: A novel modulator in tooth development
EVC2:牙齿发育的新型调节剂
  • 批准号:
    8495760
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
Role of Vwc2-assisted activin signaling in bone formation
Vwc2辅助激活素信号在骨形成中的作用
  • 批准号:
    8054102
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
EVC2: A novel modulator in tooth development
EVC2:牙齿发育的新型调节剂
  • 批准号:
    8106220
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
Role of Vwc2-assisted activin signaling in bone formation
Vwc2辅助激活素信号在骨形成中的作用
  • 批准号:
    7706943
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
EVC2: A novel modulator in tooth development
EVC2:牙齿发育的新型调节剂
  • 批准号:
    7845547
  • 财政年份:
    2009
  • 资助金额:
    $ 37.1万
  • 项目类别:
Roles of Matrix Proteoglycans in Dentin Bonding
基质蛋白多糖在牙本质粘接中的作用
  • 批准号:
    6911750
  • 财政年份:
    2004
  • 资助金额:
    $ 37.1万
  • 项目类别:

相似国自然基金

Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
  • 批准号:
    82070530
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
  • 批准号:
    32002421
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
  • 批准号:
    31902347
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Layilin as a modulator of platelet activation and thromboinflammation
Layilin 作为血小板活化和血栓炎症调节剂
  • 批准号:
    10607168
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
Impact of metabotropic glutamate receptor heteromerization on signaling and pharmacology
代谢型谷氨酸受体异聚化对信号传导和药理学的影响
  • 批准号:
    10637938
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
Structure and functional analysis of Shrew, a novel modulator of the BMP signalling pathway
BMP信号通路新型调节剂Shrew的结构和功能分析
  • 批准号:
    2898295
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
    Studentship
Structural and Allosteric Mechanisms of mGluR Activation
mGluR 激活的结构和变构机制
  • 批准号:
    10679316
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.
开发化合物 RUEC2-118,这是一种新型部分 GABAAR 正调节剂,可快速治疗一般性焦虑和恐慌症,以预防阿片类药物和苯二氮卓类药物过量死亡。
  • 批准号:
    10684503
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
O-GlcNac Modulation of GABAergic Transmission
O-GlcNac 对 GABA 能传输的调节
  • 批准号:
    10754746
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
Enhancement of the endogenous opioid system by ketamine
氯胺酮增强内源性阿片系统
  • 批准号:
    10717708
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
Biological Sex as a Modulator of Neuronal Development and Function
生物性别作为神经元发育和功能的调节剂
  • 批准号:
    10552305
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
Development of a splicing modulator compound for familial dysautonomia
开发用于家族性自主神经功能障碍的剪接调节剂化合物
  • 批准号:
    10680719
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers
支持在吸烟者 2 期临床研究中评估 mGlu2 PAM SBP-9330 的安全性/毒理学、ADME 和 CMC 活动
  • 批准号:
    10829189
  • 财政年份:
    2023
  • 资助金额:
    $ 37.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了